Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient.

Virology Journal
John S SchieffelinJames E Robinson

Abstract

Antibodies produced in response to infection with any of the four serotypes of dengue virus generally provide homotypic immunity. However, prior infection or circulating maternal antibodies can also mediate a non-protective antibody response that can enhance the course of disease in a subsequent heterotypic infection. Naturally occurring human monoclonal antibodies can help us understand the protective and pathogenic roles of the humoral immune system in dengue virus infection. Epstein-Barr Virus (EBV) transformation of B cells isolated from the peripheral blood of a human subject with previous dengue infection was performed. B cell cultures were screened by ELISA for antibodies to dengue (DENV) envelope (E) protein. ELISA positive cultures were cloned by limiting dilution. Three IgG1 human monoclonal antibodies (HMAbs) were purified and their binding specificity to E protein was verified by ELISA and biolayer interferometry. Neutralization and enhancement assays were conducted in epithelial and macrophage-like cell lines, respectively. All three HMAbs bound to E from at least two of the four DENV serotypes, one of the HMAbs was neutralizing, and all were able to enhance DENV infection. HMAbs against DENV can be successfully ge...Continue Reading

References

Oct 1, 1991·Journal of Clinical Microbiology·K MoritaA Igarashi
Jan 1, 1985·The American Journal of Tropical Medicine and Hygiene·E A HenchalW E Brandt
Apr 1, 1989·The American Journal of Tropical Medicine and Hygiene·S C KliksD S Burke
Oct 23, 1997·Molecular Biology and Evolution·M YeagerA L Hughes
Jan 14, 1999·International Immunology·G Johnson, T T Wu
Nov 1, 2001·Clinical and Diagnostic Laboratory Immunology·A J CuzzubboP L Devine
Dec 26, 2002·Annual Review of Immunology·Attila KumánovicsKirsten Fischer Lindahl
May 22, 2003·Proceedings of the National Academy of Sciences of the United States of America·Yorgo ModisStephen C Harrison
Aug 1, 1964·The Australian Journal of Experimental Biology and Medical Science·R A HAWKES
Dec 24, 2003·Advances in Virus Research·Scott B Halstead
Jan 1, 1952·The American Journal of Tropical Medicine and Hygiene·A B SABIN
Jun 18, 2004·Emerging Infectious Diseases·Hlaing Myat ThuJohn Aaskov
Aug 9, 2005·Developmental and Comparative Immunology·Harry W Schroeder
Feb 24, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kao-Jean HuangHuan-Yao Lei

❮ Previous
Next ❯

Citations

Jun 14, 2013·Applied Microbiology and Biotechnology·Xiao-Quan LiXiao-Yan Che
Sep 21, 2011·The Journal of Infectious Diseases·Anuja MathewAlan L Rothman
Oct 17, 2012·Antimicrobial Agents and Chemotherapy·Joanna L MillerNicole Zitzmann
Mar 24, 2012·Journal of Nanobiotechnology·Elisângela F SilvaLuiz F L Coelho
Jun 29, 2010·PLoS Neglected Tropical Diseases·Joshua M CostinScott F Michael
Jun 30, 2011·PLoS Neglected Tropical Diseases·Ruklanthi de AlwisAravinda M de Silva
Feb 23, 2012·Viruses·Wahala M P B Wahala, Aravinda M de Silva
May 5, 2012·The American Journal of Tropical Medicine and Hygiene·Yara A HalasaWu Zeng
Feb 8, 2013·The American Journal of Tropical Medicine and Hygiene·Nell BondDaniel G Bausch
Jan 9, 2013·Transactions of the Royal Society of Tropical Medicine and Hygiene·Meng Ling MoiIchiro Kurane
Jul 6, 2012·Bioelectrochemistry·Binh Thi Thanh NguyenChee-Seng Toh
Nov 26, 2010·Antiviral Research·Cindo O NicholsonScott F Michael
Nov 19, 2015·Expert Review of Vaccines·Eliana G Acosta, Ralf Bartenschlager
Jan 22, 2013·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Moisés León-JuárezLeticia Cedillo-Barrón
May 26, 2012·FEMS Immunology and Medical Microbiology·Xin FangXiancai Rao
Jul 25, 2013·Human Vaccines & Immunotherapeutics·Jazmín García-MachorroLeticia Cedillo-Barrón
Dec 3, 2014·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Laura L HermannBeth-Ann G Coller
May 1, 2016·Journal of Molecular Biology·David OlagnierJohn Hiscott
Jul 5, 2016·Frontiers in Immunology·Juan Carlos Yam-PucLeopoldo Flores-Romo
Dec 15, 2015·PloS One·Arturo Ramon Vargas CorreaLuciana Barros de Arruda
Oct 24, 2013·Molecular Biology and Evolution·David A RasmussenKatia Koelle
Oct 9, 2014·The American Journal of Tropical Medicine and Hygiene·Irma Y Amaya-LariosJosé Ramos-Castañeda
May 16, 2017·PLoS Neglected Tropical Diseases·Bhumi PatelAravinda M de Silva
Jan 17, 2017·Clinical & Translational Immunology·Lauren M PaulSharon Isern
Jun 13, 2014·Clinical and Vaccine Immunology : CVI·Jean-Louis ExclerStanley A Plotkin
Sep 28, 2018·Microbiology and Immunology·Nurhafiza ZainalSazaly AbuBakar
Sep 26, 2012·Nature Reviews. Immunology·Patrick C Wilson, Sarah F Andrews

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
biolayer interferometry
biosensors

Software Mentioned

Octet QK

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antibody-Dependent Enhancement

Antibody-dependent enhancement of viral infection is the entry of virus into host cells mediated by antiviral antibodies interacting with Fc or complement receptors. This has been most extensively observed with the dengue virus. Find the latest research on antibody-dependent enhancement here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.